Treatment of the naive patient.

J. G. Bartlett

Research output: Contribution to journalArticlepeer-review


The 6th Conference on Retroviruses and Opportunistic Infections included some significant information on initial HIV therapy. Data from the Dupont 006 efavirenz (EFV)/AZT/3TC trial are provided in a table and demonstrate the excellent potency and durability of efavirenz. The Atlantic Trial compares three 3-drug regimens. Twenty-four week results are presented, including evidence that median increases in CD4 counts are similar between the groups. In addition, researchers from the conference presented 24-week data from two open trials of ABT 378 in combination with Ritonavir. This drug shows great tolerability and potency. Details from each trial are discussed.

Original languageEnglish (US)
Pages (from-to)1, 10-11
JournalThe Hopkins HIV report : a bimonthly newsletter for healthcare providers / Johns Hopkins University AIDS Service
Issue number2
StatePublished - Mar 1999

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Treatment of the naive patient.'. Together they form a unique fingerprint.

Cite this